REZOLUTE INC (RZLT)
US76200L3096 - Common Stock
Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
Additional $6.7M in funding resulting in approximately $67M in gross proceeds
Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
Additional $6.7M in funding resulting in approximately $67M in gross proceeds...
Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed...
Tuesday 6/18 Insider Buying Report: LMND, RZLT
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking out on Friday as we dive into all of the biggest news moving shares this morning!
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed...
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed...
Rezolute to Participate in the Jefferies Global Healthcare Conference
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are worth checking out on Wednesday as we offer up all the latest news sending shares higher and lower this morning!
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
Met primary study endpoints: good safety profile and reduction in central subfield thickness (CST) First oral therapy to demonstrate reduction in macular...
RZLT Stock Earnings: Rezolute Misses EPS for Q3 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rezolute (NASDAQ:RZLT) just reported results for the third quarter of 2024.Rezo...
RZLT Stock Earnings: Rezolute Misses EPS for Q3 2024
RZLT stock results show that Rezolute missed analyst estimates for earnings per share the third quarter of 2024.
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI); topline results expected...
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
Discover three biotech stocks with explosive growth potential. Don't miss out on these great picks this year.
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor...